Article Correctness Is Author's Responsibility: Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL

The article below may contain offensive and/or incorrect content.

A significantly lower percentage of patients receiving a 70-mg or 140-mg dose of erenumab had severe disability during treatment compared with placebo.